The 10-second takeaway
For the quarter ended March 31 (Q1), MEDNAX met expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share increased.
Margins shrank across the board.
MEDNAX booked revenue of $422.6 million. The 12 analysts polled by S&P Capital IQ predicted net sales of $423.3 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $382.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.94. The 13 earnings estimates compiled by S&P Capital IQ predicted $1.00 per share. GAAP EPS of $0.98 for Q1 were 4.3% higher than the prior-year quarter's $0.94 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 31.6%, 70 basis points worse than the prior-year quarter. Operating margin was 18.8%, 100 basis points worse than the prior-year quarter. Net margin was 11.4%, 50 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $439.9 million. On the bottom line, the average EPS estimate is $1.19.
Next year's average estimate for revenue is $1.78 billion. The average EPS estimate is $4.72.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 175 members out of 179 rating the stock outperform, and four members rating it underperform. Among 56 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 55 give MEDNAX a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $81.17.
If you're interested in health care stocks like MEDNAX, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Click here for instant access to this free report.
- Add MEDNAX to My Watchlist.